SBIR Phase II: Microbial Discovery and Biosynthesis of Targeted Protease Inhibitors (COVID-19)

SBIR 第二阶段：微生物发现和靶向蛋白酶抑制剂（COVID-19）的生物合成

• 批准号: 2213051
• 负责人: Matthew Traylor
• 金额: $ 100万
• 依托单位: THINK BIOSCIENCE, INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2213051&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Microbial; Discovery

The broader impact/commercial potential of this Small Business Innovation Research Phase II project is to develop a mature, market-ready approach for building targeted, readily synthesizable inhibitors of viral proteases. The technology will extend the discovery platform to new targets and disease indications and build a biochemical foundation for progressing preclinical programs to promising leads, starting with a potent lead candidate for treating COVID-19. The project seeks to generate new intellectual property that covers the discovery platform and promising small molecules, and it will support new opportunities to partner with pharmaceutical companies on antiviral therapeutics, which continue to be an important unmet medical need. This Small Business Innovation Research Phase II project seeks to expand and industrialize the company’s recently demonstrated approach for using microbial systems to guide the discovery and assembly of protease inhibitors. The project focuses on COVID-19 and other viral diseases that lack effective treatments, exhibit significant epidemic potential, and/or remain relevant to U.S. biodefense. The research program may uncover inhibitors of a broad set of viral proteases and as it screens large libraries of biosynthetic pathways for targeted inhibitors. This solution complements the multi-part effort by developing a potent lead candidate for treating COVID-19 and a general workflow for the (bio)synthetic optimization of hits identified. Success in these tasks may stretch contemporary approaches to synthetic biology by applying them to the discovery and assembly of new biologically active compounds and may develop a supporting (bio)synthetic workflow—one that that combines applied enzymology and synthetic chemistry.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究阶段项目的更广泛的影响/商业潜力是开发一种成熟的，可以在市场上建立针对性，易于合成的病毒蛋白抑制剂的方法。该技术将将发现平台扩展到新的目标和疾病指示，并为有前途的潜在客户建立生化基础，从而将临床前计划延伸到有前途的潜在客户中，从潜在的候选人进行了Covid-19。该项目旨在生成涵盖发现平台并承诺小分子的新知识产权，它将支持与抗病毒治疗的制药公司合作的新机会，这仍然是重要的未满足医疗需求。这个小型企业创新研究阶段项目旨在扩展和工业化该公司最近展示的使用微生物系统来指导蛋白酶抑制剂的发现和组装的方法。该项目着重于19和其他缺乏有效治疗的病毒疾病，暴露了巨大的流行潜力，并且/或与美国生物陷入困境有关。该研究计划可能会发现一系列广泛的病毒蛋白酶的抑制剂，并在筛选针对靶向抑制剂的大量生物合成途径。该解决方案通过开发用于治疗COVID-19的潜在潜在候选者和（生物）综合优化的一般工作流程来遵守多部分的工作。这些任务中的成功可能会通过将合成生物学方法应用于新生物学的发现和组装来扩展当代的合成生物学方法，并可能开发一种支持（BEIO）合成工作流程，该工作流程应用酶学和合成化学的一种组合奖，该奖项通过评估NSF的法规效果，对Infectia的支持表示了良好的影响。